

DAFTAR PUSTAKA

- Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P. B., Schraub, S., Sneeuw, K., Sullivan, M., & Takeda, F. (2001). EORTC QLQ-C30 Scoring Manual The EORTC QLQ-C30 Introduction. *Journal of the National Cancer Institute*, 30.
- Abdel-Razeq, H., & Hashem, H. (2020). Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. *Critical Reviews in Oncology/Hematology*, 145(November 2019). <https://doi.org/10.1016/j.critrevonc.2019.102837>
- Akgül, S., Chan, B. A., & Manders, P. M. (2022). Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice. *BMC Cancer*, 22(1), 1–15. <https://doi.org/10.1186/s12885-022-09885-7>
- Aldossary, S. A. (2019). *Review on Pharmacology of Cisplatin : Clinical Use , Toxicity and Mechanism of Resistance of Cisplatin*. 12(March), 7–15.
- Alfarisa, S., Mitra, E., & Wahyuni, S. (2023). Karakteristik Pasien Kanker Paru di RSUP Dr. M. Djamil Padang Tahun 2021. *Scientific Journal*, 2(6), 141–149. <https://doi.org/10.56260/sciena.v2i6.116>
- Alfarisyi, A. M. A., Hasanah, N., & Moerad, E. B. (2025). KARAKTERISTIK PASIEN NON-SMALL CELL LUNG CARCINOMA DI RSUD ABDOEL WAHAB SJAHRANIE SAMARINDA. *Jurnal Ilmu Kedokteran Dan Kesehatan*, 12(5), 1023–1033.
- Aliyah, N., Pranggono, E., & Andriyoko, B. (2016). Kanker Paru: Sebuah Kajian Singkat. *Indonesian Journal Chest And Emergency Medicine*, 4(1), 28–32.
- American Cancer Society. (2024). *Lung Cancer*. American Cancer Society. <https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html>
- American Cancer Society. (2025). *What Is Lung Cancer?* American Cancer Society. <https://cancerstatisticscenter.cancer.org>
- Azmiardi, A., & Febrinasari, R. P. (2025). *Validity and Reliability of the Indonesian Version of Diabetes Quality of Life Brief Clinical Inventory in Patients with Type 2 Diabetes at Primary Care*. 12(August), 124–132. <https://doi.org/10.26714/magnamed.12.2.2025.124-132>
- Barbuti, A. M., & Chen, Z. (2015). *Paclitaxel Through the Ages of Anticancer*

Therapy : Exploring Its Role in Chemoresistance and Radiation Therapy. M, 2360–2371. <https://doi.org/10.3390/cancers7040897>

Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., Chou, J. F., Dulko, D., Sit, L., Barz, A., Novotny, P., Fruscione, M., Sloan, J. A., Schrag, D., Hudis, C. A., & Sabbatini, P. (2016). *Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. 34(6). <https://doi.org/10.1200/JCO.2015.63.0830>*

Brown, V., Sitzia, J., Richardson, A., Hughes, J., Hannon, H., & Oakley, C. (2001). *The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy. 38, 497–510.*

Buana, I., & Harahap, D. A. (2022). Asbestos, Radon Dan Polusi Udara Sebagai Faktor Resiko Kanker Paru Pada Perempuan Bukan Perokok. *AVERROUS: Jurnal Kedokteran Dan Kesehatan Malikussaleh, 8(1), 1. <https://doi.org/10.29103/averrous.v8i1.7088>*

Cancer Council Australia. (2020). *Understanding Lung Cancer.*

Chairudin, M. R., Marhana, I. A., & Erawati, D. (2019). Profil Pasien Kanker Paru Primer yang Dirawat Inap dan Rawat Jalan di Rumah Sakit Umum Daerah Dr Soetomo Surabaya. *Jurnal Respirasi, 5(3), 65. <https://doi.org/10.20473/jr.v5-i.3.2019.65-71>*

Chen, Y.-M., Perng, R.-P., Tsai, C.-M., & Whang-Peng, J. (2006). A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly. *Journal of Thoracic Oncology, 1(2), 141–145. [https://doi.org/10.1016/s1556-0864\(15\)31529-x](https://doi.org/10.1016/s1556-0864(15)31529-x)*

Chouaid, C., Agulnik, J., Goker, E., Herder, G. J. . H., Lester, J. F., Vansteenkiste, J., Finnen, H. W., Lungershausen, J., Eriksson, J., Kim, K., & Mitchell, P. L. R. (2013). Health-Related Quality of Life and Utility in Patients with Advanced Non – Small-Cell Lung Cancer. *JTO Acquisition, 8(8), 997–1003. <http://dx.doi.org/10.1097/JTO.0b013e318299243b>*

Ciccolini, J., Serdjebi, C., Peters, G. J., & Giovannetti, E. (2016). Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC - PAMM perspective. *Cancer Chemotherapy and Pharmacology, 78(1), 1–12. <https://doi.org/10.1007/s00280-016-3003-0>*

Culakova, E., Poniewierski, M. S., Wolff, D. A., Dale, D. C., Crawford, J., & Lyman, G. H. (2015). The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage

breast cancer : a prospective cohort study. *SpringerPlus*.
<https://doi.org/10.1186/s40064-015-1165-6>

Daroszewski, C., Stasiewicz, M., Jaźwińska-Tarnawska, E., Rachwalik, A., Mura, E., Luboch-Kowal, J., Dryś, A., Bogucki, Z. A., & Brzecka, A. (2019). Quality of life in patients with advanced non-small-cell lung cancer receiving palliative chemotherapy. *Advances in Experimental Medicine and Biology*, 1160, 11–18. https://doi.org/10.1007/5584_2019_346

Dasari, S., & Tchounwou, P. B. (2015). *Cisplatin in cancer therapy : molecular mechanisms of action*. 364–378.
<https://doi.org/10.1016/j.ejphar.2014.07.025>. Cisplatin

Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer: What does it mean on main street? *Journal of Thoracic and Cardiovascular Surgery*, 155(1), 356–359.
<https://doi.org/10.1016/j.jtcvs.2017.08.138>

DiGiovanni, J., Popovic, M., Chow, E., Cella, D., Beaumont, J. L., Nguyen, J., Chu, D., Adili, A., Pulenzas, N., Lechner, B., Lam, H., & Bottomley, A. (2016). Quality of life in patients with lung cancer. *Cancer: Treatment, Decision Making and Quality of Life*, 79–92. <https://doi.org/10.46316/1676-008-002-030>

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer*, 45(2), 228–247.
<https://doi.org/10.1016/j.ejca.2008.10.026>

European, S. for M. O. (2018). What is Non-Small-Cell Lung Cancer? Let us answer some of your questions. *ESMO Patient Guide Series*, 7.

Fiteni, F., Anota, A., Bonnetain, F., Oster, J. P., Pichon, E., Wislez, M., Dauba, J., Debieuvre, D., Souquet, P. J., Bigay-Game, L., Molinier, O., Dansin, E., Poudenx, M., Milleron, B., Morin, F., Zalcman, G., Quoix, E., & Westeel, V. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. *European Respiratory Journal*, 48(3), 861–872. <https://doi.org/10.1183/13993003.01695-2015>

Futriani, E. S., & Irsadi, D. (2025). HUBUNGAN USIA DAN DUKUNGAN KELUARGA DENGAN KUALITAS HIDUP PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RAWAT INAP RS KANKER DHARMAIS. *MAHESA : Malahayati Health Student Journal*, 5, 5049–5061.

- Ganesh, S., Lye, M. S., & Lau, F. N. (2016). Quality of life among breast cancer patients in Malaysia. *Asian Pacific Journal of Cancer Prevention*, 17(4), 1677–1684. <https://doi.org/10.7314/APJCP.2016.17.4.1677>
- Ganti, A. K., Klein, A. B., Cotala, I., Seal, B., & Chou, E. (2021). Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients with Non-Small Cell Lung Cancer in the US. *JAMA Oncology*, 7(12), 1824–1832. <https://doi.org/10.1001/jamaoncol.2021.4932>
- Gargiulo, P., Arenare, L., Gridelli, C., Morabito, A., Ciardiello, F., Gebbia, V., Maione, P., Spagnuolo, A., Palumbo, G., Esposito, G., Della Corte, C. M., Morgillo, F., Mancuso, G., Di Liello, R., Gravina, A., Schettino, C., Di Maio, M., Gallo, C., Perrone, F., & Piccirillo, M. C. (2021). Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. *BMC Cancer*, 21(1), 1–9. <https://doi.org/10.1186/s12885-021-08323-4>
- Gkogkou, P., Peponi, E., Ntaskagiannis, D., Murray, S., Demou, A., Sainis, I., Ioakeim, E., Briasoulis, E., & Tsekeris, P. (2020). E-Cadherin and Syndecan-1 Expression in Patients with Advanced Non-small Cell Lung Cancer Treated with Chemoradiotherapy. *In Vivo*, 34(1), 453–459. <https://doi.org/10.21873/invivo.11795>
- GLOBOCAN. (2022a). *Cancer Today*. <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>
- GLOBOCAN. (2022b). *Indonesia Cancer Observatory*. <https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf>
- Gridelli, C., Balducci, L., Ciardiello, F., Di Maio, M., Felip, E., Langer, C., Lilenbaum, R. C., Perrone, F., Senan, S., & De Marinis, F. (2015). Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. *Clinical Lung Cancer*, 16(5), 325–333. <https://doi.org/10.1016/j.clcc.2015.02.006>
- Haris, R. N. H., Makmur, R., Andayani, T. M., & Kristina, S. A. (2019). *Penilaian Properti Psikometrik Instrumen Kualitas (HRQoL) pada Populasi Umum : Tinjauan Sistematis Hidup*. 9(2), 65–75.
- Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446–454. <https://doi.org/10.1038/nature25183>
- Hidayati, agnia rizki, Gondodiputro, S., & Rahmiati, L. (2018). Elderly Profile of

Quality of Life Using WHOQOL-BREF Indonesian Version : A Community-Dwelling. *Althea Medical Journal*, 5(2), 105–110.

Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., Klapper, S., Hansen, K., Ramani, R., Lachs, M., Wong, F. L., & Tew, W. P. (2011). Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. *Journal of Clinical Oncology*, 29(25), 3457–3465. <https://doi.org/10.1200/JCO.2011.34.7625>

Iriandana, D. Z., Indria, D. M., Sulistyowati, E., Iriandana, D. Z., Indria, D. M., & Sulistyowati, E. (2020). Analisis Pengaruh Aspek Perawatan Kesehatan terhadap Kualitas Hidup Pasien Kanker Stadium 3 dan 4. *Jurnal Kedokteran Komunitas (Journal of Community Medicine)*, 1–7.

Jang, J. Y., Kim, D., Im, E., & Kim, N. D. (2025). Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies. *International Journal of Molecular Sciences*, 26(2), 1–17. <https://doi.org/10.3390/ijms26020796>

Jiang, S., Huang, L., Zhen, H., Jin, P., Wang, J., & Hu, Z. (2021). Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. *BMC Cancer*, 21(1), 1–7. <https://doi.org/10.1186/s12885-021-09034-6>

Johnson, D. H. (2000). Evolution of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer. In *A Historical Perspective and The Eastern Cooperative Oncology Group Experience*. The American College of Chest Physicians. <https://doi.org/10.1378/chest.117.4>

Juwita, D. A., Afdhila, R., & Almahdy. (2018). Pengaruh Karakteristik Pasien Terhadap Kualitas Hidup Terkait Kesehatan Pada Pasien Kanker Payudara di RSUP Dr . M . Djamil Padang ., *Jurnal Sains Farmasi Dan Klinis*, 5(2), 126–133.

Kang, Y., Hsieh, H., Lin, M., & Wang, C. (2025). *Correlation and Predictors of EORTC QLQ-C30 GHS-QoL and EQ-5D VAS in Patients with Advanced NSCLC* (Vol. 12, Issue 2017).

Karimi, M., & Brazier, J. (2016). Health , Health-Related Quality of Life , and Quality of Life : What is the Difference ? *PharmacoEconomics*. <https://doi.org/10.1007/s40273-016-0389-9>

Kartika Nur Aisah, S., & Bakhriansyah, M. (2013). Profil Penderita Kanker Paru Primer Di RSUD Ulin Banjarmasin Tahun 2006-2011. *Berkala Kedokteran*, 9(2), 169–180. <https://ppjp.ulm.ac.id/journal/index.php/jbk/article/view/947>

Kementerian Kesehatan, R. (2023). Komite Penanggulangan Kanker Nasional. In *PEDOMAN TATA LAKSANA KANKER PARU*.

Komite Penanggulangan Kanker Nasional. (2017). Panduan Penatalaksanaan Kanker Paru. *Kementerian Kesehatan Republik Indonesia*, 1–47. <http://kanker.kemkes.go.id/guidelines/PPKProstat.pdf>

Koswara, T., Iriawan, J., & Surya, F. (2022). Karakteristik Karsinoma Paru Bukan Sel Kecil Dan Hasil Pemeriksaan Egfr Di Rsup Dr. Hasan Sadikin Periode Tahun 2018-2020. *Medika Kartika Jurnal Kedokteran Dan Kesehatan*, 5(Volume 5 No 2), 150–161. <https://doi.org/10.35990/mk.v5n2.p150-161>

Krisnadewi, K. I., Kristina, S. A., & Wiedyaningsih, C. (2020). Estimasi Nilai Years of Life Lost (YLL) Penyakit Kanker Akibat Secondhand Smoke di Indonesia. *Majalah Farmaseutik*, 16(2), 141. <https://doi.org/10.22146/farmaseutik.v16i2.49615>

Li, A., Wei, Z. J., Ding, H., Tang, H. S., Zhou, H. X., Yao, X., & Feng, S. Q. (2017). Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: A meta-analysis of randomized clinical trials. *Oncotarget*, 8(34), 57365–57378. <https://doi.org/10.18632/oncotarget.17071>

Li, Z., Li, C., Yang, D., Song, J., Liu, T., Zhou, Z., Zhou, L., & Kang, M. (2022). Comparing the efficacy and safety of cisplatin and other platinum - based chemotherapies in locally advanced nasopharyngeal carcinoma : a systematic review and meta - analysis. *BMC Cancer*, 1–15. <https://doi.org/10.1186/s12885-022-09712-z>

Lisnadiyanti. (2019). Hubungan Karakteristik Pasien Kanker Serviks Terhadap Dukungan Sosial Pada Pasien dengan Kanker Serviks di Ruang Rawat Inap di Rumah Sakit Kanker Dharmais. *Jurnal Stikes Siti Hajar*, 32–36.

Lou G, Z., Rumgay, H., Morgan, E., Langselius, O., & Vignat, J. (2025). *Global lung cancer incidence according to subtype: new study highlights rising adenocarcinoma rates linked to air pollution*.

Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Critical Reviews in Oncology/Hematology*, 90(3), 190–199. <https://doi.org/10.1016/j.critrevonc.2013.12.006>

Maringka, P. C., Wiyono, W. I., & Antasionasti, I. (2020). Penilaian Kualitas Hidup Pada Pasien Kanker di Ruangan Irina Delima RSUP Prof. Dr. R. D. Kandou Manado. *Jurnal Biomedik:JBM*, 12(2), 139. <https://doi.org/10.35790/jbm.12.2.2020.29286>

Młyńczak, K., & Golicki, D. (2021). Validity of the EQ-5D-5L questionnaire

among the general population of Poland. *Quality of Life Research*, 30(3), 817–829. <https://doi.org/10.1007/s11136-020-02667-3>

Ms, H., A, H. D., & K, S. D. (2011). *Factors affecting quality of life in cancer patients undergoing chemotherapy*. 11(2).

Mudigubba, M. K., Rajashekarachari, Y., & Dahiya, S. (2017). Risk Factors Associated With Adverse Drug Reactions in Hospitalized Patients. *International Journal of Pharmaceutical Sciences and Research*, 8(9), 3847–3854. [https://doi.org/10.13040/IJPSR.0975-8232.8\(9\).3847-54](https://doi.org/10.13040/IJPSR.0975-8232.8(9).3847-54)

Nasution, V. S., Wahyuni, S., & Dalimunthe, G. I. (2025). *View of ANALISIS PENGGUNAAN OBAT KEMOTERAPI KANKER PARU-PARU DI RSUD DR. PIRNGADI KOTA MEDAN.pdf* (pp. 201–216).

National Cancer Institute. (2018). Chemotherapy and You: Support for People With Cancer. U.S. Department of Health & Human Services |. In *U.S. Department of Health & Human Services | National Institutes of Health*. <http://www.cancer.gov/cancertopics/coping/chemotherapy-and-you>

National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. *NCCN Guidelines*.

Nirmalasari. (2022). *Efikasi dan keamanan kemoterapi lini pertama pada pasien kanker paru karsinoma bukan sel kecil (kpkbsk) stadium lanjut*.

Nobili, S., Lavacchi, D., Perrone, G., Vicini, G., Tassi, R., Landini, I., Grosso, A., Roviello, G., Mazzanti, R., Santomaggio, C., & Mini, E. (2022). *Vinorelbine in Non-Small Cell Lung Cancer : Real-World Data From a Single-Institution Experience*. 28, 237–248.

Perhimpunan Dokter Paru Indonesia (PDPI). (2018). *Pedoman Nasional Pelayanan Kedokteran Kanker Paru*. Kementerian Kesehatan Republik Indonesia.

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., & Peters, S. (2019). Corrigendum: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv192–iv237) DOI: 10.1093/annonc/mdy275). *Annals of Oncology*, 30(5), 863–870. <https://doi.org/10.1093/annonc/mdy474>

Priliana, wiwi kustio, Indriasari, fika nur, & Pratiwi, E. (2018). *Hubungan usia, jenis kelamin dan jenis kanker terhadap kualitas hidup anak dengan kanker*. VI(1), 48–55.

Purba, F. D., Hunfeld, J. A. M., Iskandarsyah, A., Fitriana, T. S., Sadarjoen, S. S., Ramos-Goñi, J. M., Passchier, J., & Busschbach, J. J. V. (2017). The Indonesian EQ-5D-5L Value Set. *PharmacoEconomics*, 35(11), 1153–1165.

<https://doi.org/10.1007/s40273-017-0538-9>

Quinten, C., Martinelli, F., Coens, C., Sprangers, M. A. G., Ringash, J., Gotay, C., Bjordal, K., Greimel, E., Reeve, B. B., Maringwa, J., Ediebah, D. E., Zikos, E., King, M. T., Osoba, D., Taphoorn, M. J., Flechtner, H., Schmucker-Von Koch, J., Weis, J., & Bottomley, A. (2014). A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. *Cancer*, 120(2), 302–311. <https://doi.org/10.1002/cncr.28382>

Rahayu, S. M., & Suprapti, T. (2021). Kualitas Hidup Pasien Kanker Yang Menjalani Kemoterapi Di Bandung Cancer Society. *Jurnal Wacana Kesehatan*, 5(2), 551. <https://doi.org/10.52822/jwk.v5i2.148>

Ramalingam, S., & Belani, C. P. (2004). Paclitaxel for non-small cell lung cancer. *Expert Opinion on Pharmacotherapy*, 5(8), 1771–1780. <https://doi.org/10.1517/14656566.5.8.1771>

Reynaldi, A., Trisyani W, Y., & Adiningsih, D. (2020). Kualitas Hidup Pasien Kanker Paru Stadium Lanjut. *Jnc*, 3(2), 71–79.

Riset Kesehatan Dasar (Riskesdas). (2018). Laporan Riskesdas 2018 Nasional.pdf. In *Lembaga Penerbit Balitbangkes* (p. hal 156). [https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan Riskesdas 2018 Nasional.pdf](https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan_Riskesdas_2018_Nasional.pdf)

Rusdi, N. K., Sari, E. N., & Wulandari, N. (2023). Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021. *Jurnal Sains Dan Kesehatan*, 5(3), 313–323. <https://doi.org/10.25026/jsk.v5i3.1754>

Salim, S., Yamin, M., Alwi, I., & Setiati, S. (2015). *Validity and Reliability of the Indonesian Version of SF-36 Quality of Life Questionnaire on Patients with Permanent Pacemakers*. 49(1), 10–16.

Salsabila, S., Intan, S. A., & Fitrina, D. W. (2023). Gambaran Tipe Sel Karsinoma Paru Primer Berdasarkan Usia , Jenis Kelamin ,. *Jurnal Ilmu Kesehatan Indonesia*, 04(04), 281–288.

Sarfati, D., Koczwara, B., & Jackson, C. (2016). The impact of comorbidity on cancer and its treatment. *CA: A Cancer Journal for Clinicians*, 66(4), 337–350. <https://doi.org/10.3322/caac.21342>

Scagliotti, B. G. V, Marinis, F. De, Rinaldi, M., Crino, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., Altavilla, G., Adamo, V., Ceribelli, A., Clerici, M., Costanzo, F. Di, Frontini, L., Tonato, M., & Cancer, L. (2002). *Phase III Randomized Trial Comparing Three Platinum-Based*

Doublets in Advanced Non – Small-Cell Lung Cancer. 20(21), 4285–4291.
<https://doi.org/10.1200/JCO.2002.02.068>

Schiller, J. H., Harrington, D., Belani, chandra p., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, david h. (2002). *Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer*. 346(2), 92–98.

Setiawan, M., Lestari, D. R., & Rachmawati, K. (2018). Hubungan Lama Kemoterapi Dengan Konsep Diri Pasien Kanker Payudara. *Dinamika Kesehatan*, 9(2), 429–443.

Siddiqui, I. A., Sanna, V., Ahmad, N., Sechi, M., & Mukhtar, H. (2015). Resveratrol nanoformulation for cancer prevention and therapy. *Annals of the New York Academy of Sciences*, 1348(1), 20–31. <https://doi.org/10.1111/nyas.12811>

Sivabalan Logawathi, S., & Causa Trisna Mariedina. (2020). Characteristics of Lung Cancer Patients in Haji Adam Malik General Hospital Medan in 2016-2018. *Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)*, 2(1), 31–39. <https://doi.org/10.32734/jetromi.v2i1.3280>

Siwi, A. S., Sumarni, T., Fadly, A. R., & Hidayat, A. I. (2021). *Kualitas Hidup pada Pasien Kanker yang Menjalani Kemoterapi*. 340–3347.

Sofianidi, A., Karadimou, A., Charpidou, A., & Syrigos, K. N. (2024). *The Gap of Health Inequalities Amongst Lung Cancer Patients of Different Socioeconomic Status : A Brief Reference to the Greek Reality*. 1–16.

Sukma, A. A. mawadani, Yuliyanasari, N., Prijambodo, T., & Primadina, N. (2020). *JURNAL IMPLEMENTA HUSADA* 117 *Jurnal.umsu.ac.id/index.php/JIH* 117. 1(2), 117–125.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

Suwendar, S., Fudholi, A., Andayani, T. M., & Sastramihardja, H. S. (2019). KUALITAS HIDUP PENDERITA KANKER SERVIKS BERDASARKAN. *Jurnal Ilmiah Farmasi Farmasyi*, 2(2), 111–117.

Syolihan, D., Putri, R., & Haryanti, S. D. (2024). Gambaran Tanda-Tanda Vital Pasien Kanker Paru Sebelum Dan Sesudah Menjalani Kemoterapi Description of Vital Signs of Lung Cancer Patients Before and After Chemotherapy. *Journal of Nursing Care & Biomolecular*, 9(1), 2024–2025.

Szabo, S. M., Griffin, E., Iannaccone, S. T., Gooch, K. L., & Audhya, I. F. (2025). interpretation of descriptive systems from patient and caregiver perspectives.

Advances in Patient-Reported Outcomes, 1(3), 100209.
<https://doi.org/10.1016/j.apro.2025.100209>

Tan, V. S., Tjong, M. C., Chan, W. C., Yan, M., Delibasic, V., Darling, G., Davis, L. E., Doherty, M., Hallet, J., Kidane, B., Mahar, A., Mittmann, N., Parmar, A., Tan, H., Wright, F. C., Coburn, N. G., & Louie, A. V. (2023). Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis. *Current Oncology*, 30(3), 3461–3472.
<https://doi.org/10.3390/currncol30030262>

Toffart, A., Moro-sibilot, D., Couraud, S., Merle, P., Perol, M., Girard, N., Souquet, P., Mastroianni, B., Ferretti, G. R., & Romand, P. (2014). *Evaluation of RECIST in chemotherapy-treated lung cancer : the Pharmacogenoscan Study*. 4–10.

Tomasini, P., Barlesi, F., Mascaux, C., & Greillier, L. (2016). Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes. *Therapeutic Advances in Medical Oncology*, 8(3), 198–208. <https://doi.org/10.1177/1758834016644155>

Tondok, S. B., Watu, E., & Wahyuni, W. (2021). Validitas instrumen European Quality of Life (EQ-5D-5L) Versi Indonesia untuk menilai kualitas hidup penderita tuberkulosis. *Holistik Jurnal Kesehatan*, 15(2), 267–273.
<https://doi.org/10.33024/hjk.v15i2.4759>

Toschi, L., & Cappuzzo, F. (2009). Gemcitabine for the treatment of advanced nonsmall cell lung cancer. *Oncotargets and Therapy*, 2, 209–217.
<https://doi.org/10.2147/ott.s4645>

Van Nguyen, C., Nguyen, H. T. T., Nguyen, T. N. L., Dao, L. K., Thi, H. T. T., & Huy, K. T. P. (2025). Health-Related Quality of Life of Non-Small Cell Lung Cancer Patients Treated with Targeted Therapy: Based on the EQ-5D-5L Scale in Vietnam. *Asian Pacific Journal of Cancer Prevention*, 26(4), 1277–1283.
<https://doi.org/10.31557/APJCP.2025.26.4.1277>

Wahyuni, A. S., Zain-Hamid, R., Syafiuddin, T., & Bacthiar, A. (2016). ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ-MEDAN) AS ALTERNATIVE ASSESSMENT FOR THE QUALITY OF LIFE IN PATIENTS WITH ASTHMA IN MEDAN CITY, INDONESIA. *International Journal of Advanced Research*, 4(9), 1135–1140.
<https://doi.org/10.21474/IJAR01/1594>

Wahyuni, F. A., Supadmi, W., & Yuniarti, E. (2023). Hubungan Regimen Kemoterapi Terhadap Kualitas Hidup Pasien Kanker Di Rumah Sakit PKU Muhammadiyah Yogyakarta. *Pharmacia*, 1(2), 1–11.

Wan Puteh, S. E., Razali, H., Ismail, A., & Zulkifli, M. (2024). Health status based

on EQ-5D-5L for the cancer patient population in Malaysia. *Scientific Reports*, 14(1), 1–9. <https://doi.org/10.1038/s41598-024-58844-8>

Widyasanti, D., Sutanto, Y. S., Septiawan, D., Aphridasari, J., & Reviono, R. (2025). Effects of Hypnotherapy on Pain Scale, Interleukin-6 Levels, and Quality of Life in Lung Cancer Patients Who Experience Cancer Pain. *Jurnal Respirologi Indonesia*, 45(3), 174–183. <https://doi.org/10.36497/jri.v45i3.624>

Wintner, L. M., Giesinger, J. M., Zabernigg, A., Sztankay, M., Meraner, V., Pall, G., Hilbe, W., & Holzner, B. (2013). Quality of life during chemotherapy in lung cancer patients: Results across different treatment lines. *British Journal of Cancer*, 109(9), 2301–2308. <https://doi.org/10.1038/bjc.2013.585>

Wulandari, A., Monalisa, S., & Zaini, J. (2019). Analisis biaya kemoterapi lini pertama pada pasien kanker paru di rumah sakit persahabatan Jakarta Timur periode tahun 2016. *Sainstech Farma*, 12(2), 85–92.

Yang, S. C., Kuo, C. W., Lai, W. W., Lin, C. C., Su, W. C., Chang, S. M., & Wang, J. Der. (2019). Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. *Journal of Thoracic Oncology*, 14(11), 1892–1900. <https://doi.org/10.1016/j.jtho.2019.07.007>

Yildirim, M., Yildiz, M., Dilli, U. D., Öztürk, D., Duman, B. B., & Çelik, B. (2013). Comparison of taxan-cisplatin combination with gemcitabine -cisplatin combination in metastatic non-small cell lung cancer. *Gulhane Medical Journal*, 55(1), 32–35. <https://doi.org/10.5455/gulhane.18081>

Yuniarti, E., Supadmi, W., Wahyuni, F. A., & Ratna, R. (2021). Kualitas Hidup Pasien Kanker yang Menjalani Kemoterapi di Rumah Sakit Yogyakarta. *Prosiding University Research Colloquium*, 594–606.

Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer : current treatment and future advances. *Translational Lung Cancer Research*, 5(I), 288–300. <https://doi.org/10.21037/tlcr.2016.06.07>